Dr. Gail Cross is an Infectious Diseases physician with interest in Tuberculosis, HIV and infections in the immunocompromised host. She graduated with BSc (UNSW, 2000) and MBBS (Monash University, 2006) and was awarded the FRACP (Infectious Diseases) in 2014. She has worked in multiple states in Australia, in Papua New Guinea and currently resides and works in Singapore. Her research interests are primarily in Tuberculosis.
Current Research:
- Co-Investigator in Rosuvastatin as adjunctive therapy for Drug Susceptible Pulmonary Tuberculosis, a Randomised-Controlled Trial (ROSETTA), National University Hospital.
- Trial Management Group, Two-month Regimens Using Novel Combinations to Augment Treatment effectiveness for drug-sensitive Tuberculosis (TRUNCATE-TB), National University Hospital.
- Primary Investigator. COVID-19 responses in the Immunocompromised Host (V-RICH) study
- Co-Investigator in COVID-19 Serology in Low-Risk patients admitted to hospital with Acute Respiratory Infection, National University Hospital.
- Co-Investigator in TY0127 trial for patients with COVID-19, NUH
- Co-Investigator. An untranslated region of the HIV genome predicting for major drug resistance. National University Hospital, Singapore.
- Collaborator. Topotecan for COVID-19 patients, a Phase II randomised controlled trial, National University Hospital, Singapore.